UCLA Blood Test Pushes Multi-Cancer Detection Toward Routine Screening Costs
Researchers at UCLA Health have developed MethylScan, a blood-based assay designed to detect multiple cancers and several liver diseases from a single sample at a cost the team says can stay under $20. The central advance is not only analytical performance, but the way the test compresses a complex genomic workflow into something that begins to resemble a realistic population screening tool. By reading methylation patterns in cell-free DNA and stripping away a large portion of background leukocyte DNA before sequencing, the method attempts to preserve the signal of disease while lowering the cost barrier that has kept many multi-cancer assays outside ordinary practice.
The test’s strongest appeal is its balance of breadth and specificity. Across cancers of different stages, MethylScan reached 63% overall detection and roughly 55% for early-stage disease, with 98% specificity. In screening medicine, specificity this high matters because false positives can rapidly erode the value of any broad-based assay, especially one intended for asymptomatic populations. A test that sends too many healthy people into downstream imaging, biopsy, or specialist referral quickly loses both clinical and economic credibility.
cfDNA Methylation Signals and the Problem of Background Noise
The platform works by analyzing methylation signatures in circulating cell-free DNA, a biologic approach that makes sense for tumors because malignant tissue sheds fragments into the bloodstream with epigenetic marks that differ from normal cells. The technical challenge has always been signal dilution. Most cell-free DNA in blood comes from non-tumor sources, so cancer-associated patterns can be buried under ordinary hematopoietic material before sequencing ever begins.
MethylScan addresses that problem by depleting background leukocyte DNA before the sequencing step. That pre-analytic choice appears to be a key reason the assay can remain inexpensive while still preserving diagnostic performance. In practical terms, the workflow reduces waste: fewer irrelevant fragments are sequenced, fewer reads are needed to recover useful disease-associated patterns, and the resulting assay becomes less dependent on large, expensive sequencing runs. For a screening test, cost is not a secondary issue. It is part of the test’s clinical validity because affordability determines whether the assay can reach the people who would benefit from earlier detection.
Cancer Detection Performance Was Strongest in Liver Disease Cohorts
The most striking results came from high-risk liver populations. Among patients with liver cirrhosis or hepatitis B, MethylScan detected nearly 80% of liver cancers. It also distinguished between different liver disease etiologies with about 85% accuracy. In a field where chronic liver disease often creates a confusing background of inflammation, fibrosis, and malignant transformation, that level of discrimination is clinically meaningful.
Liver cancer surveillance has long suffered from imperfect tools. Ultrasound-based monitoring can miss early lesions, while blood biomarkers have not consistently provided the sensitivity needed to change outcomes at the stage when intervention is most effective. A methylation-based assay offers a different biological angle. Cancer arises not just from gene mutations, but from widespread epigenetic reprogramming that alters how DNA is packaged and read. Those patterns may become detectable before a tumor grows large enough to be obvious on imaging, especially in patients already known to be at elevated risk because of hepatitis or cirrhosis.
One sentence captures the immediate clinical tension: early-stage cancers were still easier to miss than advanced disease.
Early-Stage Detection Remains the Hardest Test of the Platform
The 55% detection rate for early-stage cancers is a reminder that sensitivity at the point of greatest clinical value remains incomplete. Screening succeeds only when it identifies disease early enough to change the trajectory, not merely when it confirms already established cancer. A multi-cancer blood test can look impressive in aggregate and still leave a meaningful gap in the very setting where survival gains are most plausible.
That gap does not negate the advance. It defines the next engineering problem. Early cancers shed less DNA, and the fraction of tumor-derived fragments in circulation can be vanishingly small. A platform that improves background subtraction and methylation readout is moving in the right direction, but the biology of low-volume disease still limits how much signal can be recovered from a single tube of blood. Any future iteration will need to preserve specificity while improving sensitivity for those earliest lesions, when intervention can matter most.
Why the Price Point Could Change Adoption
The under-$20 estimate may prove as important as the detection statistics. Multi-cancer early detection tests have often faced a familiar obstacle: even when performance is promising, the cost structure makes population use unrealistic. A low-cost assay could shift the conversation from boutique testing toward targeted use in higher-risk cohorts, especially in liver disease surveillance where the pretest probability is already elevated.
A price this low also changes the mathematics of implementation. If a test can be deployed broadly enough in patients with hepatitis B, cirrhosis, or other liver risk factors, the threshold for net clinical benefit becomes easier to approach. Fewer resources would be spent on each specimen, and the downstream burden from unnecessary follow-up could be moderated by the assay’s 98% specificity. That combination makes the platform relevant not only as a scientific achievement, but as a possible screening instrument that health systems could realistically evaluate.
What the Data Support, and What They Do Not Yet Prove
These findings support the feasibility of a low-cost, methylation-based blood test for multi-cancer detection, with a particularly strong signal in liver cancer surveillance. They do not yet establish that the test improves mortality, replaces standard surveillance strategies, or performs equally well across all cancer types and stages in real-world practice. Those are separate questions, and they require prospective validation in broader populations before any claim about routine use can be made with confidence.
For now, the most defensible reading is narrower: MethylScan appears to have enough specificity, enough low-cost scalability, and enough performance in high-risk liver disease cohorts to justify further clinical development. The remaining question is not whether methylation biology can be measured in blood. It already can. The open issue is whether this approach can be refined enough to catch more early cancers without losing the precision that makes screening workable in the first place.